

# STATE OF ALASKA

Department of Administration  
Office of Procurement and Property  
Management



## STATEWIDE FORENSIC TOXICOLOGY TESTING

RFP 2024-0200-0034

Amendment ONE

August 30, 2023

**The purpose of this amendment is to address the following changes/additions:**

- A. The date for this solicitation is extended to 10:00 a.m. Alaska Time, September 12, 2023.**
- B. Provide an updated Attachment C to provide update based on the question from the vendor community and to add another sheet for value add options (not scored).**
  - a. Added language to row 2 to provide clarification regarding alterations and pricing with regards to GC/MS Confirmation.**
  - b. Removed line items related to**
    - i. 1-Difluroethane (DFE), Blood (#1)**
    - ii. 6-Monoacetylmorphine - Free (Unconjugated), Fluid (#2)**
    - iii. Alcohol Confirmation, Blood (#3)**
    - iv. Alcohol Panel, Blood (#4)**
    - v. Alcohol Screen, Blood (#6)**
    - vi. Bath Salts Panel, Blood (#11)**
    - vii. Carbon Monoxide Exposure Biouptake Confirmation, Blood (#17)**
    - viii. Carbon Monoxide Exposure Biouptake Screen, Blood (#18)**
    - ix. Cortisol (#22),**
    - x. Environmental exposure (#29)**
    - xi. GC/MC confirmation(#31)**
    - xii. Inhalants Panel, Blood (#35)**
    - xiii. Nicotine and Metabolite Confirmation, Blood (Forensic) (#39)**
    - xiv. Non-law enforcement, controlled substance....(#40)**
    - xv. Petroleum Distillates Panel, Blood (#42)**
    - xvi. Synthetic Cannabinoids Screen & Confirm, Blood (#62)**
    - xvii. Volatiles Screen, Blood (#66)**
  - c. Clarified line #9 to replace confirmation with the word panel**

- d. Clarified line #36 to alkane gases from abused gases
- e. Two Line #25s and #26 identified; Drug Facilitated Sexual Assault Panel, Blood renumbered to (#68), Drug Impaired Driving/DRE Toxicology Panel (with Alcohol), Blood (Forensic) renumbered to (#69)
- f. Added Specimen Return/Handling (#70) to cost proposal
- g. Clarification regarding tests and panels: 11-Hydroxy-delta-9 THC compound should be included in DUI-Drug work. Also, it should clear that labs testing for THC compounds can differentiate between the Delta-9 and Delta-8 isomers.

**C. Provide answers to questions from potential offerors:**

1. **Question: Under Section 3.03 – Deliverables, reports can be transmitted by telephone, computer, fax or any other method of delivery.**
  - a. Does the State of Alaska have a case management software program that would need to be interfaced with for report delivery?
  - b. Will there be a requirement to have an interface under this new contract?
  - c. Will the interface capability be considered in the evaluation criteria?

**Answer:**

*The current vendor for the case management system is VertiQ. Whereas this contract can be used by other entities, this is something that would be worked out with ordering agencies and will not be part of the evaluation criteria.*

2. **Question: In Section 3.07 it states any payment of \$1M or higher must be accepted via EFT. Will payments under this amount also be made via EFT?**

**Answer:**

*Payments less than \$1,000,000 may be made in a variety of forms, including ACH/EFT, PCard, and check (warrant).*

3. **Question: Section 1.04 and Section 3.03: In Section 1.04, the turnaround time expectations are stated as 15 days and in Section 3.03, it is stated as 14 days. Can you please clarify the desired turnaround time?**

**Answer:**

*Section 1.04 has been amended to reflect 14 days.*

4. **Question: In Attachment C Cost Proposal Spreadsheet: Is it acceptable for offerors to provide test codes for each line item/test name to the right of the annual cost column (so as not to alter the existing information)?**

**Answer:**

*Attachment C has been updated to allow for offerors to provide test codes/names for what the offeror equivalent panels/tests may be. For any variations from what is being asked, another column has been provided to provide specifics of what the offeror equivalent. IT has also been updated to include a sheet for value-add items.*

5. **Question: The pricing that you have requested lists products that appear to be the incumbent laboratory. Each laboratory has unique products that are used for test ordering, frequently referred to as “panels”. A panel is a group of tests for multiple compounds of interest. As an example, the incumbent Postmortem Basic includes testing**

for multiple specific compounds, which likely differ somewhat from other similarly qualified and accredited laboratories' grouping of compounds into panels/products. Other jurisdictions accept and award proposals to laboratories whose products are similar and equivalent to the requested products. Since products are very lab dependent and we do not offer a panel called Postmortem Basic, Blood, how should we complete the form to price products specific to a single laboratory, given the instruction provided on the form to make no alterations? (I.e. How would Ford price Chevrolet products?)

*Answer: Attachment C has been updated to reflect the ability to provide an equivalent offering, in the event you are providing a similar equivalent indicate accordingly in column "D" and note the specifics of what it includes in the appropriate column "E".*

- 6. Question: May we have actual case count and actual spending with the incumbent laboratory over the last 12 months?**

*Answer: Please refer to Section 1.02 of the RFP for available information.*

- 7. Question: Section 1.07 Return Instructions states, "All proposals must be submitted via email. The technical proposal and cost proposal must be saved as separate PDF/EXCEL documents and emailed to joshua.hartman@alaska.gov as separate, clearly labeled attachments, such as "Vendor A – Technical Proposal.pdf" and "Vendor A – Cost Proposal.pdf". The maximum size of a single email (including all text and attachments) that can be received by the state is 20mb (megabytes)." Is it acceptable to provide the documents in a zip file?**

*Answer: No. If required due to restriction on the maximum size send the document in multiple emails and label accordingly (1 of 3, 2 of 3, etc...).*

- 8. Attachment B Offeror Response Worksheet, page 2: "Contract Team and Key Staff identified, and resumes included, as a separate attachment (not to be counted against the maximum page limits)." We have over 25 toxicologists/key scientific staff. Would it be acceptable to provide brief biographies of this staff (at 11pt font the bios alone are over 9 pages) and resumes of our Laboratory Director and Senior Vice President of Forensic Sciences, with all other resumes available upon request?**

*Answer: Yes, it is acceptable to provide brief bios in lieu of resumes for the scientific staff along with resumes of the key leadership positions, with the understanding that the other resumes are available upon request.*

- 9. Question: With regard to the handful of products where our offering is significantly broader, what is the best way for us to price the equivalent test and not be penalized in the cost scoring? How do we account for tests that may be needed in the future but not identified?**

*Answer: Offerors should do their best to provide comparable offerings to what has been requested. In the event that you have products that may appear to be superior than what is requested feel free to add this to the value add sheet of the proposal. The cost proposal has identified the tests that have been identified to be the most essential, however, additional tests not identified may be requested if included in the value-add portion, or referenced with a discount percentage (i.e. all additional tests not identified for the cost evaluation receive a discount of xx%).*

**10. Question: Can the State please provide instruction on how to indicate on the cost spreadsheet that a test is not available?**

*Answer: Highlight the test and provide a comparable equivalent and appropriate note as indicated in the answer for Question 9.*

**11. Question: Is a panel which includes screening with reflexed confirmatory testing acceptable?**

*Answer: Yes.*

**12. Question: There is insufficient information about the incumbent offering to identify the equivalent. Can an order code and spec sheet from the incumbent lab be provided?**

*Answer: Details have been provided below in section D. Additionally this information is publicly available online for comparison.*

**13. Question: One approach that has been seen in other RFPs for forensic toxicology from other jurisdictions is to use a narrower listing of products in the cost scoring rubric (those which comprise 90-95% of the testing/spending volume), plus a discount off list pricing for all other testing orders, which tends to be more variable and likely encompasses testing not listed on your cost proposal sheet. This provides flexibility in the future as new relevant analytes are identified, so the Medical Examiner Office can have a contract that evolves and stays relevant. Would narrowing the list to the ten items highlighted on the cost proposal sheet be an acceptable alternative approach?**

*Answer: The cost proposal has identified the tests that have been identified to be the most essential, however, additional tests not identified may be requested if included in the value-add portion, or referenced with a discount percentage (i.e. all additional tests not identified for the cost evaluation receive a discount of xx%). In the event that you have products that may appear to be superior than what is requested, or are not requested please add this to the value add sheet of the proposal.*

**14. Question: Attachment B Offeror Response Worksheet – 5.04, 5.05, 5.06, 5.07 Evaluation questions: Are offerors to include these evaluation questions in their responses and, if so, do they go against the page limitations?**

*Answer: The questions themselves do not count against the page limitations.*

**D. Descriptions of select panels/tests to provide additional clarification:**

**#28 Electrolytes and Glucose Panel (Vitreous), Fluid (Forensic):**

Analyte(S)	Synonym(S)
Chloride (Vitreous Fluid)	Cl-
Creatinine (Vitreous Fluid)	
Glucose (Vitreous Fluid)	C6H12O6; D-glucose (biologically active); Dextrose; L-glucose
Potassium (Vitreous Fluid)	K+

Analyte(S)	Synonym(S)
Sodium (Vitreous Fluid)	Na+
Urea Nitrogen (Vitreous Fluid)	Carbamide; carbonyl diamide; carbonyldiamine

### #36 Inhalants Panel, Alkane Gases, Blood

Analyte(S)	Synonym(S)
Ethane	
Isobutane	
Methane	
n-Butane	
Propane	

### #37 Inhalants Panel, Solvents and Gases, Blood

Analyte(S)	Synonym(S)
1,1,1,2-Tetrafluoroethane	Dymel 134a; Genetron 134a; HFC-134a; norflurane; R134a; Suva 134a; tetrafluoroethane
1,1-Difluoroethane	Freon 152a
Ethane	
Halocarbons	
Isobutane	
Methane	
n-Butane	
Propane	
Volatiles	

### #41 Novel Psychoactive substances (NPS) Screen 1, Blood

Analyte(S)	Synonym(S)
2-fluoro Deschloroketamine	
3-hydroxy-PCP	
4-ANPP	
Acetyl Fentanyl	
Alpha-Hydroxyetizolam	
alpha-PHP / alpha-PiHP	
Benzylone	
Bromazepam	
Butylone	
cis-3-Methylfentanyl	
Clonazepam	
Cyclopropylfentanyl	
Deschloroketamine	
Diclazepam	

<b>Analyte(S)</b>	<b>Synonym(S)</b>
Ethylone	
Etizolam	
Eutylone	
Fentanyl	
Flualprazolam	
Flubromazepam	
Flubromazolam	
Isobutyrylfentanyl	
Methoxyacetylfentanyl	
N-butyl Pentylone	
N-ethyl Pentylone	
Norfentanyl	
ortho-Fluorofentanyl	
para-Fluorofentanyl	
Pentylone	
Phenazepam	
trans-3-Methylfentanyl	
Valeryl fentanyl	
3-MeO-PCP	3-Methoxy-Phencyclidine
para-Fluoroisobutyrylfentanyl	4F-Isobutyrylfentanyl; FIBF
Acrylfentanyl	Acryloylfentanyl
alpha-PVP	alpha-pyrrolidinopentiophenone; alpha-Pyrrolidinovalerophenone
Dibutylone	bk-DMBDB
Butyrylfentanyl	Butyrfentanyl
Carfentanil	Carfentanyl; Wildnil®
Delorazepam	Chlordesmethyldiazepam; Cloxazolam metabolite
2-Furanylfentanyl	Fu-F; Furanylfentanyl
Mitragynine	Kratom
U-47700	U-4

#### **#58 Postmortem Toxicology – Urine Screen Add-on (6-MAM Quantification only)**

<b>Analyte(S)</b>	<b>Synonym(S)</b>
Amphetamines	
Barbiturates	
Benzodiazepines	
Cannabinoids	
Cocaine / Metabolites	
Fentanyl / Metabolite	
Methadone / Metabolite	
Opiates	
Oxycodone / Oxymorphone	
Phencyclidine	Angel Dust; PCP; Sherm

### #61 Synthetic Cannabinoids Screen, Blood (Forensic)

Analyte(S)	Synonym(S)
MDMB-4en-PINACA 4-fluoro-BINACA 3,3-dimethylbutanoic acid 4-fluoro-MDMB-BINACA	4-fluoro MDMB BINACA butanoic acid metabolite 4-fluoro-MDMB-BUTINACA
5-fluoro-PINACA 3-methylbutanoic acid	5-fluoro AMB metabolite 7
5-fluoro-PICA 3,3-dimethylbutanoic acid	5-fluoro MDMB-PICA metabolite 7
5-fluoro-PINACA 3,3-dimethylbutanoic acid	5-fluoro-ADB metabolite
5-fluoro-MDMB-PINACA / 5-fluoro-EMB-PINACA	5-fluoro-ADB/5-fluoro-AEB
5-fluoro-MDMB-PICA / 5-fluoro-EMB-PICA	5-fluoro-EMB-PICA
FUBINACA 3-methylbutanoic acid	AB-FUBINACA metabolite 3
ADMB-CHMINACA	ADB-CHMINACA; MAB-CHMINACA
ADMB-FUBINACA	ADB-FUBINACA
MMB-FUBINACA	AMB-FUBINACA, FUB-AMB
APP-BINACA	APP-BUTINACA
FUBINACA 3,3-dimethylbutanoic acid	MDMB-FUBINACA metabolite 1

### #65 Volatiles Panel, Hydrocarbon and Oxygenated, Blood

Analyte(S)	Synonym(S)
1,1,1-Trichloroethane	Methyl Chloroform
1,1,2,2-Tetrachloroethane	
Acetone	
Benzene	
Carbon Tetrachloride	Tetrachloromethane
Chloroethane	
Chloroform	
Chloromethane	
Dichlorodifluoromethane	Freon 12
Dichloroethane	
Dichloromethane	Methylene Chloride
Ethanol	Ethyl Alcohol
Ethyl Ether	Diethyl Ether
Iso-Amyl Alcohol	Amyl Nitrite Metabolite
Isobutanol	Iso-Butyl Nitrite Metabolite; Isobutyl Alcohol
Isopropanol	Isopropyl Alcohol
m-Xylene	
Methanol	Methyl Alcohol
Methyl Ethyl Ketone	MEK

n-Butanol	Butyl Alcohol; Butyl Nitrite Metabolite
o-Xylene	
p-Xylene	
Toluene	
Trichlorofluoromethane	Freon 11
Trichlorotrifluoroethane	Freon 113
Xylenes (o,m,p) - Total	

**E. Additional panel clarification provided in the Excel Spreadsheet labeled Toxicology Scope of Work.**

**ALL OTHER TERMS AND CONDITIONS REMAIN UNCHANGED.**